9340 Federal Register / Vol. 60, No. 33 / Friday, February 17, 1995 / Notices

orthopedic procedures. Bone marrow

transplantation has also been

successfully performed. More recently

enzyme replacement therapy has

become available using a mannose

terminated form human

glucocerebrosidase. This therapy, often

costing $100,000 to $300,000 per adult

patient annually, has effectively

improved biochemical and hematologic

manifestations of this disorder in many

patients and has reversed

hepatosplenomegaly. The optimal

dosing for this preparation is still under

investigation. Also, other novel

strategies for enzyme therapy and gene

therapy for Gaucher disease are being

actively pursued.

The purpose of this Technology

Assessment Conference is to evaluate

current concepts concerning diagnosis,

genetic counseling, and management of

Gaucher disease. The conference will

bring together epidemiologists,

geneticists, pediatricians, neurologists,

obstetricians, orthopedists,

hematologists, genetic counselors,

clinical pathologists, others involved in

health care delivery, as well as

representatives of the public to review

available data and make

recommendations regarding population

screening, genetic counseling, and

current patient management as well as

for future research.

After 1-1⁄2 days of presentations and

audience discussion, an independent,

non-Federal panel will weigh the

scientific evidence and write a draft

statement that it will present to the

audience on the third day. The

statement will address the following key

questions:

What is the natural history of Gaucher

disease and what is the appropriate

technology to assess the severity and to

predict the progression of this disorder?

What are the roles of current

molecular and enzymatic assays for

ascertaining affected individuals and

carriers in various populations?

What are the indications for treatment

of patients with Gaucher disease and

what are the appropriate modes of

therapy?

What are the goals for and

consequences of treatment and how can

the therapeutic interventions be

assessed?

Under what circumstances could

genotype/phenotype correlations be

used for patient care and counseling?

What are the appropriate directions

for future research?

The primary sponsors for this

conference are the National Institute of

Mental Health and the NIH Office of

Medical Applications of Research. The

conference is cosponsored by the

National Institute of Child Health and

Human Development, the National

Institute of Diabetes and Digestive and

Kidney Diseases, the National Institute

of Neurological Disorders and Stroke,

the National Center for Research

Resources, and the National Center for

Human Genome Research.

Advance information on the

conference program and conference

registration materials may be obtained

from: Debra DeBose, Technical

Resources International, Inc., 3202

Tower Oaks Blvd., Suite 200, Rockville,

Maryland 20852, (301) 770–3153.

The technology assessment statement

will be submitted for publication in

professional journals and other

publications. In addition, the statement

will be available beginning March 1,

1995 from the NIH Consensus Program

Information Service, P.O. Box 2577,

Kensington, Maryland 20891, phone 1–

800–NIH–OMAR (1–800–644–6627).

Dated: February 10, 1995.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 95–3991 Filed 2–16–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meetings of the

following Heart, Lung, and Blood

Special Emphasis Panels.

These meetings will be open to the

public to provide concept review of

proposed contract or grant solicitations.

Individuals who plan to attend and

need special assistance, such as a sign

language interpretation or other

reasonable accommodations, should

inform the Contact Person listed below

in advance of the meeting.

Name of Panel: NHLBI SEP on Pulmonary

Vascular Biology.

Dates of Meeting: March 9, 1995.

Time of Meeting: 8:00 a.m.

Place of Meeting: National Institutes of

Health, Building 31C, Conference Room 8,

Bethesda, Maryland.

Agenda: The panel will review the current

status of research in the designated areas,

identify gaps and make recommendations

regarding opportunities and priorities for

future contract or grant solicitations.

Contact Person: Dorothy B. Gail, Ph.D.,

5333 Westbard Avenue, Room 6407,

Bethesda, Maryland 20892, (301) 549–7428.

Name of Panel: NHLBI SEP on TB/AIDS.

Dates of Meeting: March 21, 1995.

Time of Meeting: 8:30 a.m.

Place of Meeting: National Institutes of

Health, Natcher, Building 45, Conference

Room C–1, Bethesda, Maryland 20892.

Agenda: The panel will review the current

status of research in the designated areas,

identify gaps and make recommendations

regarding opportunities and priorities for

future contract or grant solicitations.

Contact Person: Hannah H. Peavy, M.D.,

5333 Westbard Avenue, Room 6A09,

Bethesda, Maryland 20892 (301) 594–7428.

Name of Panel: NHLBI SEP on Critical

Care.

Dates of Meeting: March 28, 1995.

Time of Meeting: 8:30 a.m.

Place of Meeting: National Institutes of

Health, Natcher, Building 45, Conference

Room C–1, Bethesda, Maryland 20892.

Agenda: The panel will review the current

status of research in the designated areas,

identify gaps and make recommendations

regarding opportunities and priorities for

future contract or grant solicitations.

Contact Person: Carol H. Bosken, M.D.,

5333 Westbard Avenue, Room 6A07,

Bethesda, Maryland 20892, (301) 549–7428.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: February 9, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–3988 Filed 2–16–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meeting:

Name of SEP: Demonstration and

Education Research Applications.

Date: March 14–15, 1995.

Time: 9:00 a.m.

Place: Stouffer Concourse Hotel, Arlington,

VA.

Contact Person: Dr. Louise Corman, 5333

Westbard Avenue, Room 548, Bethesda, MD

20892, (301) 594–7452.

Purpose/Agenda: To review and evaluate

grant applications.

The meeting will be closed in accordance

with the provisions set forth in sec.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)